Thursday's Health Winners & Losers

Novavax is rising.
Author:
Publish date:

Novavax

(NVAX) - Get Report

was one of Thursday's best health care performers, rising 13.7%. The company announced that industry expert John Lambert will become executive chairman of the board, succeeding new lead director Gary Evans. Novavax was adding 38 cents to $3.15.

Express Scripts

(ESRX)

raised its hostile bid for

Caremark

(CMX)

late Wednesday. Express Scripts said it expects the Federal Trade Commission to make a second request for information on the offer. Express Scripts was rising by 3.1% to $77.10, and Caremark was up 1.7% at $62.35.

Drugstore chain

CVS

(CVS) - Get Report

, which announced in November that it will merge with Caremark in an all-stock deal valued near $21 billion, was higher by 2.7% at $32.15.

On the other hand,

Hollis-Eden Pharmaceuticals

(HEPH)

slumped 31.8% after the Department of Health and Human Services said Neumene, a treatment for acute radiation syndrome, is technically unacceptable. The government also canceled a proposal for bids for radiation drugs under the government's Project Bioshield antiterrorism initiative. Hollis-Eden was down $1.36 at $2.92.

Elsewhere,

MedcoHealth

(MHS)

was rising 2.9% to $69.73.

Celgene

(CELG) - Get Report

was higher by 2.1% at $57.75.

InterMune

(ITMN)

was gaining 1.1% to $22.44.

Among decliners,

Adams Respiratory Therapeutics

(ARXT)

was lower by 2.7% to $37.53.

Amylin Pharmaceuticals

(AMLN)

was down 1.4% at $36.40.

Elan

(ELN)

slipped 1% to $12.92.